CureVac NV CVAC:NASDAQ

RT Quote | Last NASDAQ LS, VOL From CTA | USD
after hours iconAfter Hours: Last | 4:32 AM EDT
3.02quote price arrow up+0.05 (+1.68%)
Volume
209
Close
2.97quote price arrow up+0.06 (+2.06%)
Volume
224,758
52 week range
2.21 - 12.36
Loading...
  • Open0.00
  • Day High0.00
  • Day Low0.00
  • Prev Close2.97
  • 52 Week High12.36
  • 52 Week High Date06/23/23
  • 52 Week Low2.21
  • 52 Week Low Date04/25/24

Key Stats

  • Market Cap666.188M
  • Shares Out224.31M
  • 10 Day Average Volume0.59M
  • Dividend-
  • Dividend Yield-
  • Beta2.54
  • YTD % Change-29.45

KEY STATS

  • Open0.00
  • Day High0.00
  • Day Low0.00
  • Prev Close2.97
  • 52 Week High12.36
  • 52 Week High Date06/23/23
  • 52 Week Low2.21
  • 52 Week Low Date04/25/24
  • Market Cap666.188M
  • Shares Out224.31M
  • 10 Day Average Volume0.59M
  • Dividend-
  • Dividend Yield-
  • Beta2.54
  • YTD % Change-29.45

RATIOS/PROFITABILITY

  • EPS (TTM)-1.30
  • P/E (TTM)-2.28
  • Fwd P/E (NTM)-3.31
  • EBITDA (TTM)-270.846M
  • ROE (TTM)-49.55%
  • Revenue (TTM)57.892M
  • Gross Margin (TTM)-131.34%
  • Net Margin (TTM)-483.96%
  • Debt To Equity (MRQ)8.09%

EVENTS

  • Earnings Date05/21/2024
  • Ex Div Date-
  • Div Amount-
  • Split Date-
  • Split Factor-

Latest On CureVac NV

 

Profile

MORE
CureVac AG is a clinical-stage biopharmaceutical company, The Company strives to create transformative medicines to protect and improve people’s lives. Fueled by proprietary RNA technology platform combined with two decades of science and manufacturing, The Company is dedicated to creating novel treatments that enable the body to make its own prophylactic and therapeutic drugs.
Malte Greune Ph.D.
Chief Operating Officer, Member of the Management Board
Pierre Kemula
Chief Financial Officer, Member of the Management Board
Address
Friedrich-Miescher-Str. 15
Tuebingen
72076
Germany

Top Peers

SYMBOLLASTCHG%CHG
ANAB
AnaptysBio Inc
23.99+0.58+2.48%
NRIX
Nurix Therapeutics Inc
13.94+0.43+3.18%
TNGX
Tango Therapeutics Inc
7.31+0.20+2.89%
ZNTL
Zentalis Pharmaceuticals Inc
11.75-0.79-6.30%
YMAB
Y-mAbs Therapeutics Inc
12.19-0.09-0.73%